The DISTAL trial was funded by the Swiss National Science Foundation Gottfried und Julia Bangerter-Rhyner-Stiftung, Medtronic, Stryker Neurovascular, Phenox, Rapid Medical, and Penumbra.

Thrombectomy does not improve outcomes among patients with acute ischemic strokes caused by blockages in the medium or distal vessels, results of three randomized trials indicate. Adding endovascular ...

DISTAL was funded by the Swiss National Science Foundation, Gottfried & Julia Bangerter-Rhyner Stiftung, and unrestricted grants from Stryker Neurovascular, Medtronic, Phenox, Rapid Medical ...

Stryker (NYSE: SYK) + announced a deal to sell its U.S. spine implants business to investment firm Viscogliosi Brothers, which will call the new company VB Spine. Also after the market closed yest ...

Stryker has agreed to sell its U.S. spinal implants business to Viscogliosi Brothers to create a newly formed company called VB Spine. The medical technology company said Tuesday the New York City ...

Note: Fourth quarter and full year 2024 had one more selling day than 2023. In the fourth quarter 2024, we reorganized our Spine business to align with certain updates to our internal reporting ...

Medical technology company Stryker plans to sell its U.S. spinal implants business to investment firm Viscogliosi Brothers for an undisclosed amount, the company announced Tuesday. The deal is ...

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein’s ...

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today a definitive agreement to sell its U.S. spinal implants business ...

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Full Year Results “We ...